As filed with the U.S. Securities and Exchange Commission on December 11, 2025. Registration No. 333-291598 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biodexa Pharmaceuticals PLC (Exact name of registrant as specified in its charter) England and Wales 2834 Not Applicable (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) (IRS Em ...

As filed with the U.S. Securities and Exchange Commission on December 8, 2025. Registration No. 333-291598 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biodexa Pharmaceuticals PLC (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) England and Wales 2834 Not Applicable (Primary Standard Industrial Classification Code Number) (IRS Emp ...

Registration No. 333-291598 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM F-1 As filed with the U.S. Securities and Exchange Commission on December 8, 2025. REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biodexa Pharmaceuticals PLC (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) England and Wales 2834 Not Applicable (Primary Standard Industrial Classification Code Number) (IRS Emp ...

As filed with the U.S. Securities and Exchange Commission on November 17, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biodexa Pharmaceuticals PLC (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) England and Wales 2834 Not Applicable (Primary Standard Industrial Classification Code Number) (IRS Employer Identification No. ...

文章核心观点 - 临床阶段生物制药公司Biodexa宣布其治疗1型糖尿病的托利米酮2期研究招募到首位患者 [1][2] 托利米酮1型糖尿病2期研究情况 - 该研究由阿尔伯塔大学糖尿病研究所开展，为研究者发起的试验，将测量3个月后C肽水平和糖化血红蛋白与基线相比的情况，以及最初12名分属3个剂量组患者的高血糖事件数量，研究后续可能扩大 [3] 托利米酮在1型糖尿病方面研究情况 - 阿尔伯塔大学多项临床前研究证明托利米酮在1型糖尿病方面的潜在效用，其能诱导从人类尸体分离的β细胞增殖 [4] 托利米酮基本信息 - 托利米酮最初由辉瑞发现，曾开展治疗胃溃疡的2期研究，因缺乏疗效而停止开发，它是Lyn激酶的选择性激活剂，可增强胰岛素信号级联反应 [5] 公司主要信息 - Biodexa是临床阶段生物制药公司，致力于开发创新产品管线，治疗未满足医疗需求的疾病，总部和研发设施位于英国加的夫 [6][10] 公司主要研发项目 - eRapa是雷帕霉素的口服片剂配方，用于家族性腺瘤性息肉病和非肌肉浸润性膀胱癌的治疗，雷帕霉素是mTOR抑制剂，mTOR在肿瘤发生时被激活 [6][7] - 托利米酮是口服的Lyn激酶强效选择性抑制剂，可在糖尿病动物模型中通过胰岛素增敏实现血糖控制，有望成为一流的血糖调节剂 [6][8] - MTX110是组蛋白脱乙酰酶抑制剂帕比司他的增溶制剂，可通过对流增强递送将化疗剂量药物直接送达肿瘤部位，绕过血脑屏障并避免全身毒性 [6][9]

Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON AUGUST 12, 2024 THE SECURITIES ACT OF 1933 Biodexa Pharmaceuticals PLC (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) England and Wales 2834 Not Applicable (Primary Standard Industrial Classification Code Number) (IRS Employer Identification No.) Caspia ...